Stage migration in clinically localized prostate cancer.

Standard

Stage migration in clinically localized prostate cancer. / Noldus, J; Graefen, M; Haese, Alexander; Henke, R P; Hammerer, P; Huland, H.

In: EUR UROL, Vol. 38, No. 1, 1, 2000, p. 74-78.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Noldus, J, Graefen, M, Haese, A, Henke, RP, Hammerer, P & Huland, H 2000, 'Stage migration in clinically localized prostate cancer.', EUR UROL, vol. 38, no. 1, 1, pp. 74-78. <http://www.ncbi.nlm.nih.gov/pubmed/10859445?dopt=Citation>

APA

Noldus, J., Graefen, M., Haese, A., Henke, R. P., Hammerer, P., & Huland, H. (2000). Stage migration in clinically localized prostate cancer. EUR UROL, 38(1), 74-78. [1]. http://www.ncbi.nlm.nih.gov/pubmed/10859445?dopt=Citation

Vancouver

Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. EUR UROL. 2000;38(1):74-78. 1.

Bibtex

@article{9ea6edbf0e764b819cbc8b9ba0edf466,
title = "Stage migration in clinically localized prostate cancer.",
abstract = "OBJECTIVES: To determine whether migration of pathological tumor stages in patients with clinically localized prostate cancer exists and whether this is due to an increasing frequency of treating patients with clinically insignificant cancer. METHODS: 1,063 radical retropubic prostatectomies were performed in patients with clinically localized prostate cancer in one institution within 7.5 years (from 1992 until June 1999). All specimens were prospectively processed according to the Stanford protocol. These were then analyzed regarding the migration of pathological tumor stages and cancer volumes. RESULTS: Within the observation period, the annual rate of radical retropubic prostatectomies increased by 225% from 69 to 224 cases. The authors noted a decline of advanced tumor stages (from 65 to 40%) and an increase in pathological T2 tumors (from 30 to 55%). The rate of small cancers (",
author = "J Noldus and M Graefen and Alexander Haese and Henke, {R P} and P Hammerer and H Huland",
year = "2000",
language = "Deutsch",
volume = "38",
pages = "74--78",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Stage migration in clinically localized prostate cancer.

AU - Noldus, J

AU - Graefen, M

AU - Haese, Alexander

AU - Henke, R P

AU - Hammerer, P

AU - Huland, H

PY - 2000

Y1 - 2000

N2 - OBJECTIVES: To determine whether migration of pathological tumor stages in patients with clinically localized prostate cancer exists and whether this is due to an increasing frequency of treating patients with clinically insignificant cancer. METHODS: 1,063 radical retropubic prostatectomies were performed in patients with clinically localized prostate cancer in one institution within 7.5 years (from 1992 until June 1999). All specimens were prospectively processed according to the Stanford protocol. These were then analyzed regarding the migration of pathological tumor stages and cancer volumes. RESULTS: Within the observation period, the annual rate of radical retropubic prostatectomies increased by 225% from 69 to 224 cases. The authors noted a decline of advanced tumor stages (from 65 to 40%) and an increase in pathological T2 tumors (from 30 to 55%). The rate of small cancers (

AB - OBJECTIVES: To determine whether migration of pathological tumor stages in patients with clinically localized prostate cancer exists and whether this is due to an increasing frequency of treating patients with clinically insignificant cancer. METHODS: 1,063 radical retropubic prostatectomies were performed in patients with clinically localized prostate cancer in one institution within 7.5 years (from 1992 until June 1999). All specimens were prospectively processed according to the Stanford protocol. These were then analyzed regarding the migration of pathological tumor stages and cancer volumes. RESULTS: Within the observation period, the annual rate of radical retropubic prostatectomies increased by 225% from 69 to 224 cases. The authors noted a decline of advanced tumor stages (from 65 to 40%) and an increase in pathological T2 tumors (from 30 to 55%). The rate of small cancers (

M3 - SCORING: Zeitschriftenaufsatz

VL - 38

SP - 74

EP - 78

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 1

M1 - 1

ER -